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Tyrosine kinase inhibitors (TKIs) targeting signaling molecules downstream B cell receptor (BCR) are powerfully
spreading in the therapeutic landscape of B cell lymphoproliferative disease, due to a manageable toxicity profile
and encouraging clinical effectiveness. In particular, ibrutinib, previously called PCI-32765, is a potent inhibitor of
Bruton tyrosine kinase (Btk), recently approved for the treatment of relapsed mantle cell lymphoma (MCL) and
chronic lymphocytic leukemia (CLL). Moreover, idelalisib (formerly GS-1101 and CAL-101) is a selective reversible
inhibitor of the p110δ isoform of phosphoinositol 3 kinase (PI3K) approved for the treatment of patients with relapsed
follicular lymphoma (FL) and CLL. These agents directly affect the neoplastic clone, disrupting the supportive platform
provided by BCR signaling cascade and by other microenvironmental mutualistic interactions, and also interfering with
chemokine gradients and adhesive properties of neoplastic B cells. In the present review, we describe the clinical
efficacy of ibrutinib and idelalisib in CLL and B cell non-Hodgkin lymphoma (B-NHL), then focusing on the mode
of action (MOA) of these TKIs towards the neoplastic B cell compartment. At last, the review would further expand the
view on potential additional targets of ibrutinib and idelalisib belonging to other microenvironmental cellular elements.
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Signaling from the B cell receptor (BCR) is essential for
normal B cell development and controls several cellular
functions such as proliferation, apoptosis, differentiation,
and cell migration [1]. Constitutive activation of BCR is
a common hallmark of B cell malignancies, including
chronic lymphocytic leukemia (CLL), mantle cell lymph-
oma (MCL), follicular lymphoma (FL), and diffuse large
B cell lymphoma (DLBCL), observation that has led the
design of a novel panel of inhibitors targeting kinases
responsible for BCR signal transduction. In particular,
Bruton tyrosine kinase (Btk) and phosphoinositol 3 kinase
(PI3K) δ are pivotal signaling molecules early positioned
downstream the BCR cascade. Ibrutinib, previously called
PCI-32765, is a potent (IC50 0.5 nmol/L) inhibitor of Btk
that is inactivated through irreversible covalent binding to
Cys-481 in the ATP-binding domain of the kinase. Idelalisib
(formerly GS-1101 and CAL-101) is a selective reversible* Correspondence: rossana.maffei@unimore.it
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creativecommons.org/publicdomain/zero/1.0/inhibitor of the p110δ isoform of PI3K. The encour-
aging results of clinical trials using these tyrosine kinase
inhibitors (TKIs) envision a possible shift towards a non-
chemotherapy treatment era in B cell lymphoproliferative
diseases.
In the present review, we focused on ibrutinib,
approved by the Food and Drug Administration (FDA)
in November 2013 for the treatment of relapsed MCL
and in February 2014 as a second-line treatment for
CLL and idelalisib, which was approved by FDA in July
2014 for the treatment of patients with relapsed FL or
relapsed small lymphocytic lymphoma (SLL) and CLL,
pointing the attention to the clinical efficacy in CLL and
B cell non-Hodgkin lymphomas (NHL), the antitumor
mode of action (MOA) and the possible effects of these
drugs on non-malignant cells in tumor microenvironment.Clinical efficacy of TKIs
Ibrutinib
Since the first evaluation of ibrutinib in a phase 1 trial in a
wide setting of B cell malignancies, it was demonstratedticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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and induced clinical objective responses (60 %) across B
cell histologies, with highest response rate in MCL and
CLL patients [2]. Ibrutinib treatment was then investigated
in relapsed CLL patients in a phase 1b/2 multicenter
clinical trial conducted on 85 patients (33 % with
17p13 deletion), reporting an overall response rate
(ORR) of 71 %, with two complete responses (CR), and
further 18 % with partial response (PR) with lymphocy-
tosis. At 26 months, the progression-free survival (PFS)
was 75 % [3]. The response to ibrutinib did not vary ac-
cording to traditional high-risk prognostic factors, with
68 % of response in 17p13-deleted setting, even if most
events associated with disease progression occurred in
patients with high-risk cytogenetics (PFS = 57 %)
(Table 1). The most common adverse events were diar-
rhea, fatigue and upper respiratory tract infections. The
events of infection mainly occurred in the early phase
of treatment, but collectively, the incidence of grade 3
infections did not result increased as compared to rates
reported after traditional therapies. It was also reported
that the levels of IgG and IgM remained relatively
stable, whereas IgA increased throughout treatment [3].
The efficacy of ibrutinib in previously treated CLL was
also confirmed in a phase 3 multicenter study in which
391 patients were randomized to receive ibrutinib or
anti-CD20 antibody ofatumumab [4]. The ORR was
43 % (all partial responses) with additional 20 % PR
with lymphocytosis in ibrutinib-treated patients as
compared to only 4 % in the ofatumumab arm. Ibrutinib
in comparison to ofatumumab significantly prolonged the
duration of PFS and the rate of OS, regardless of high-risk
features. The frequencies of any grade or grade >3 infec-
tions in the ibrutinib group were 70 and 24 %, respectively
[4]. Very recently, Byrd and colleagues reported updated
observations indicating that ibrutinib treatment is well tol-
erated in CLL patients for an extended period (3-year
follow-up) and responses are durable and improves in
quality (median time to CR, 21 months), being disease
progression uncommon, and primarily occurring in the
high-risk patient settings with 17p or 11q deletions in
leukemic clone [5]. Ibrutinib is currently investigated in
combination with both chemotherapy and monoclonal
antibodies to reduce the extent of lymphocytosis and to
achieve higher frequencies of complete responses. Burger
and colleagues reported the results of a phase 2 study con-
ducted on 40 high-risk CLL patients treated with ibrutinib
plus rituximab [6]. The ORR was 95 %, with 87 % PR and
8 % CR, and the PFS at 18 months was 78 % for all
patients and 72 % for 17p-deleted/mutated patients. Infec-
tions were the most common adverse effects. Overall, the
combination strategy was associated with a shorter dur-
ation of lymphocytes redistribution as compared to
ibrutinib alone, and complete remissions were achievedin more patients. A randomized study comparing ibrutinib
versus ibrutinib plus rituximab is ongoing (NCT02007044).
As first-line monotherapy, a phase 1b/2 multicenter trial
conducted on 29 elderly symptomatic CLL patients re-
ported encouraging results with 71 % ORR (13 % CR)
and rare hematological toxicity and infections, indicating
that ibrutinib treatment is well tolerated and effective in
elderly setting. Median serum levels of IgA increased dur-
ing treatment, no changes in IgM and IgG over time [7].
As upfront strategy, two phase 3 trials are ongoing com-
paring the efficacy of chlorambucil or ibrutinib in elderly
CLL (RESONATE-2, NCT01722487) and the efficacy of
bendamustine-rituximab versus ibrutinib-rituximab versus
ibrutinib (NCT01886872). In a very recent phase 1b study
evaluating the safety and efficacy of ibrutinib in combin-
ation with chemoimmunotherapy (CIT) (bendamustine,
rituximab (BR); fludarabine, cyclophosphamide and rituxi-
mab (FCR)) in patients with relapsed/refractory CLL, the
ORR in the BR-ibrutinib group was 93 % with 40 % CR
with an expected toxicity profile and PFS 70 % at
36 months; all three patients receiving FCR-ibrutinib
achieved CR. The treatment-related lymphocytosis was
reduced, but not completely absent when ibrutinib was
combined to BR [8]. A phase 3 randomized trial com-
bining ibrutinib with BR in relapsed/refractory CLL/
SLL (NCT01611090) and a phase 2 study combining
ibrutinib with FCR in untreated, young CLL patients
(NCT02251548) are ongoing. Another recent report of
a phase 2 study conducted on 51 treatment naïve and
relapsed/refractory CLL patient harboring TP53 aberra-
tions reported activity of single-agent ibrutinib in this
high-risk subset with ORR at 24 weeks of 92 % (50 %
PR and 42 % PR with lymphocytosis) and PFS at 24
months of 82 % [9]. Rapid disease control was achieved
in all tissue compartments and durable responses were
reported, but deep remissions were rare, even in previ-
ously untreated patients. Noteworthy, subclones carrying
17p13 deletion seemed equally sensitive to ibrutinib as
those without the deletion [9].
Ibrutinib also showed antitumor activity in several
types of NHL as single agent or in combination [2, 10].
Wang et al. reported the results of a phase 2 study con-
ducted on 111 patients with relapsed or refractory MCL
treated with a daily dose of 560 mg of single-agent ibru-
tinib. The treatment showed durable efficacy with ORR
of 68 % (21 % CR) and PFS of 14 months [11]. There
was an increase of MCL cells in blood 10 days after
treatment initiation in 34 % of patients, with a subse-
quent decline in these cells to near baseline by day 28
[11]. In patients with relapsed DLBCL, ibrutinib showed
preferential activity against tumors with the activated B
cell-like (ABC) subtype with a response of 40 % [12]. In
a phase 1b study, 32 patients with B-NHL received
ibrutinib plus rituximab, cyclophosphamide, doxorubicin,
Table 1 Clinical trials with ibrutinib and idelalisib in CLL patients
Study First line or treated subset Phase Number of
patients
Age, median
(range)
Scheme ORR (CR) PFS TP53 (%) ORR (CR) PFS
All cases All cases TP53 subset TP53 subset
Byrd, NEJM 2013 [3] Relapsed 1b/2 85 66 (37–82) Ibru mono 71 + 18a (2 %) 75 % at 26 ms 33 % 68 % (4 %) 57 % at 26 ms
O’Brian, Lancet Oncol
2014 [7]
First line 1b/2 29 71 (65–84) Ibru mono 71 + 13 %a (13 %) 96 % at 24 ms 6 % NA NA
Farooqui, lancet Oncol
2015 [9]
Treated or untreated with TP53
aberrations
2 51 62 (33–82) Ibru mono - - 100 % 50 + 42 %a 82 % at 24 ms
Byrd, NEJM 2014 [4] Relapsed/refractory 3 391 67 (30–86)b Ibru vs. Ofa 43 + 20 %a (0 %) 88 % at 6 ms 32 % NA 83 % at 6 ms
Burger, Lancet Oncol
2014 [6]
High-risk previously treated or
untreated
2 40 63 (35–82) Ibru + RTX 95 % (8 %) 78 % at 18 ms 50 % 100 % (10 %) 72 % at 18 ms
Brown, Blood 2014 [14] Relapsed/refractory 1 54 63 (37–82) Ide mono 39 + 33 %a (0 %) 50 % at 16 ms 24 % 54 % (0 %) 50 % at 3 ms
Furman, NEJM 2014 [15] Relapsed 3 220 71 (48–90)b Ide + RTX vs.
placebo
81 % (0 %) 93 % at 6 ms 38 % NA NA
Ibru ibrutinib, Ide idelalisib, RTX rituximab, Ofa ofatumumab, mono monotherapy, ORR overall response rate, CR complete response, PFS progression-free survival; ms months, NA not available
aThe percentages are the ORR (CR and PR) + the PR with persistent lymphocytosis
bData of ibrutinib or idelalisib arm
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results, also in the subset of DLBCL, and acceptable safety
profile with known toxicities associated with R-CHOP
treatment [13]. A phase 3 clinical trial (NCT01855750) to
assess the clinical outcome of ibrutinib plus R-CHOP in
patients with ABC-DLBCL lymphoma is ongoing.Idelalisib
Idelalisib was first evaluated in a phase 1 trial conducted
on 54 relapsed/refractory CLL patients, showing an ORR
of 72 % with 39 % PR and 33 % PR with treatment-
induced lymphocytosis and median PFS of 16 months
for all patients. In 13 patients harboring 17p13 deletion
and/or TP53 mutation, the ORR was 54 % and median
PFS of 3 months (Table 1). In addition, idelalisib was
well tolerated, not leading to myelosuppression or an in-
crease in risk of infection as compared to the level
already reported in the heavily pretreated CLL popula-
tion [14]. The combination of idelalisib plus rituximab
was inspected in 220 relapsed CLL in a phase 3 multi-
center randomized trial that reported acceptable safety
profile and improvement in ORR (81 vs. 13 %, all PR), in
PFS at 6 months (93 vs. 46 %) and in OS at 12 months
(92 vs. 80 %) in the idelalisib group as compared to the
placebo group [15]. As in the case of ibrutinib, the
addition of rituximab to idelalisib blunted and shortened
the duration of treatment-related lymphocytosis.
Idelalisib was also evaluated in two phase 1 studies
[16, 17], enrolling 40 patients with relapsed/refractory
MCL and 64 patients with relapsed indolent NHL,
respectively. In MCL, the ORR was 40 % with 85 % of
patients having a reduction in lymph node size and
5 % of CR. Treatment-related lymphocytosis was infre-
quent in MCL setting and the median PFS was 3.7
months [16]. The response rates reported in MCL
treated with idelalisib are comparable to those ob-
tained with other single-agent treatments, including
bortezomib, lenalidomide and temsirolimus, but the
response duration seems particularly brief. Idelalisib is
well tolerated and active also in heavily pretreated,
relapsed/refractory patients with indolent NHL, in-
cluding FL, SLL, marginal zone lymphoma (MZL), and
lymphoplasmacytic lymphoma (LPL), showing ORR of
47 % and median PFS at 7.6 months [17]. Gopal et al.
reported the results of a phase 2 trial conducted on
125 patients with relapsed indolent NHL treated with
single-agent idelalisib confirming the antitumor efficacy
(ORR = 57 %, with 6 % CR and median PFS of 11 months)
and an acceptable safety profile with low rates of discon-
tinuation due to toxicity and a low incidence of severe ad-
verse events in this setting [18]. Phase 3 trials of idelalisib
in combination with rituximab (NCT01838434) and bend-
amustine/rituximab (NCT01569295) are underway.Ibrutinib and idelalisib targeting neoplastic B cells
Ibrutinib
Uncontrolled BCR signaling plays a major role in the
development and progression of B cell NHL and CLL.
Btk is required for intracellular transduction of BCR
signaling. In fact, Btk is activated by the upstream Src-
family kinases Blk, Lyn, and Fyn, and in turn, phos-
phorylates phospholipase-Cγ (PLCγ) leading to calcium
mobilization and activation of nuclear factor κB (NF-κB),
and mitogen-activated protein kinase (MAPK) pathways.
Moreover, Btk mutations cause the inherited disease
X-linked agammaglobulinemia (XLA) in human and
X-linked immunodeficiency (Xid) in mice, implying
lack of peripheral blood B cells and low levels of serum
immunoglobulins [19, 20]. So, the primary deficit associ-
ated with Btk disruption is B cell specific. In addition, Btk
is involved in signaling of other cell-surface receptors,
such as chemokine receptors and adhesion molecules that
are essential for B cell trafficking and homing. Btk belongs
to tyrosine kinase expressed in hepatocellular carcinoma
(Tec) kinase family also including Bmx, inducible T cell
kinase (Itk), resting lymphocyte kinase (Rlk) and Tec, pref-
erentially expressed in the hematopoietic system. In par-
ticular, Tec/Btk and Itk/Rlk are mediators of BCR and T
cell receptor (TCR) signaling, respectively. Itk is also
expressed in mast cells and natural killer (NK) cells.
Btk shows constitutive activity in CLL cells and is a
critical kinase for CLL development and expansion [21].
Ibrutinib exerts a direct effect by disrupting the BCR
and NF-κB signaling. In particular, ibrutinib MOA com-
prises (i) modest induction of apoptosis dependent on
caspase pathway activation, (ii) inhibition of prolifera-
tion, (iii) prevention of CLL response to survival stimuli
provided by microenvironment, and (iv) impairment of
migration and adhesion [22–24] (Fig. 1). Treatment with
ibrutinib also mediates apoptotic stimuli on normal B
cells but at lower extent in respect to CLL cells. CLL
cells have been shown to effectively increase the survival
in response to several microenvironmental stimuli such
as CD40L, B cell activating factor (BAFF), TNFα, IL6
and IL4 or contact with stromal cells and nurse-like
cells (NLCs). Ibrutinib significantly counteracted the
protection mediated by such stimuli on CLL cells [23,
22]. Noteworthy, CpG- and NLC-induced CLL prolifer-
ation was also inhibited by treating cells with ibrutinib.
In NOD/SCID/γchain (NGS) mouse xenograft model,
Herman et al. [25] recapitulated ibrutinib-mediated in-
hibition of BCR and NF-κB signaling, attenuation of
CLL proliferation and survival, and reduction of tumor
burden in vivo [25]. Concordantly, ibrutinib was shown
to down-regulate BCR and NF-κB signaling, decrease
the expression of surface activation markers CD69 and
CD86, and reduce proliferation of CLL cells from both
peripheral blood and tissue compartments in treated
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Fig. 1 Ibrutinib and idelalisib target CLL cells. The picture summarizes the main mechanisms of action of ibrutinib and idelalisib in CLL. In particular,
both agents are able to interfere with BCR signaling cascade by inhibiting the phosphorylation of Btk and PI3Kδ molecules respectively, thus limiting
the activation of pivotal pro-survival pathways in CLL cells, i.e., NF-κB, ERK, mTOR, and GSK3 pathways. As consequence, ibrutinib and idelalisib induce
pro-apoptotic signaling on CLL cells. They also impair actin polymerization and interfere with chemokine and adhesion receptors, thus leading
to ineffective migration and adhesion. Ibrutinib and idelalisib hamper protective stimuli mediated by soluble factors and by interaction with
NLC and stromal cells. BCR B cell receptor, Btk Bruton tyrosine kinase, PI3Kδ phosphoinositol 3 kinase δ, NLC nurse-like cells
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impaired actin polymerization and migration in response
to tissue-homing chemokines (CXCL12, CXCL13) and
also down-regulated the expression of BCR-dependent
chemokines (CCL3, CCL4). The ability of ibrutinib to
cause transient early lymphocytosis and profoundly inhibit
CLL progression was modeled in an adoptive transfer
TCL1 mouse setting, resembling the transient surge in
peripheral lymphocyte count characteristically observed
in CLL patients treated with ibrutinib [22]. In fact, in
ibrutinib-treated CLL patients, a fraction of leukemic cells
equal to 23 % of tissue disease burden redistributes into
the blood, leading to a rapid resolution of enlarged lymph
nodes [28]. Overall, it was clearly demonstrated that
ibrutinib impairs BCR- or chemokine-controlled integrin-
mediated adhesion or migration, implying attenuated re-
tention and homing of CLL cells in tissue compartment,thus explaining transient peripheral lymphocytosis seen in
treated patients.
Davis et al. [29] firstly identified Btk in a siRNA screen
as an essential kinase for survival of ABC-DLBCL, indicat-
ing ibrutinib as an agent able to promote apoptosis [29].
In spontaneous canine lymphoma model, ibrutinib was re-
ported to efficaciously inhibit BCR signaling downstream
of Btk and induce objective clinical responses [30]. It was
clearly demonstrated that BCR and MYD88 signaling
pathways together with sustained expression of IRF4 pro-
mote ABC-DLBCL survival by inducing NF-κB. Treat-
ment of ABC-DLBCL cells with ibrutinib decreased IRF4
protein, reduced NF-κB signaling, increased interferon
(IFN) β production, and also synergized with lenalidomide
in killing lymphoma cells in vitro and in mouse model
[31]. Furthermore, Btk is robustly expressed in malignant
plasma cells from >85 % of multiple myeloma (MM)
Maffei et al. Journal of Hematology & Oncology  (2015) 8:60 Page 6 of 13patients and in lymphoplasmacytic cells from Waldenström
macroglobulemia (WM). In MM, ibrutinib was shown
to decrease CXCL12-mediated migration, down-modulate
CCL3, and affect MM cell growth and survival triggered
by IL6 or contact with stromal cells [32, 33]. Similar in-
hibitory effects on proliferation and survival, CCL3/CCL4
secretion, and CXCL12 signaling occur in hairy cell
leukemia (HCL) treated with ibrutinib [34].
Idelalisib
PI3K pathway is well known as a key survival mechanism
in many cancers, including CLL and B-NHL. It integrates
and transmits signals from several surface receptors includ-
ing BCR, chemokine receptors and adhesion molecules,
thereby controlling survival, proliferation and migration
[35]. PI3K type I enzyme converts PtdIns(3,4)P2 into
PtdIns(3,4,5)P3 that recruits in the cell membrane via
binding to pleckstrin homology domain several down-
stream signaling molecules such as Tec kinases, Akt,
integrin-linked kinase, and Rac guanine exchange factor.
The δ isoform is one of the four catalytic isoforms of PI3K
class I, also comprising p110α, p110β, and p110γ. The
p110α and p110β are ubiquitously expressed, whereas the
p110δ isoform is generally restricted to hematopoietic cell
type and highly expressed in lymphoid cells. B cell defects,
comprising lack of B1 lymphocytes, reduced number of
mature B cells and impaired antibody production were
reported in mice with deleted or mutated PI3Kδ,
whereas knockout mice for PI3Kγ showed predominantly
T cell defects [36].
PI3Kδ is homogenously expressed in CLL cells and
also present in normal B cells, even if it shows higher in-
trinsic activity in leukemic cells. It is also expressed in
normal T cells and NK cells [37, 38]. Pre-clinical studies
demonstrated that idelalisib exerts a dose-dependent
cytotoxicity on CLL cells primarily by induction of
caspase-dependent apoptosis, instead showing less effect
on normal B cells. In CLL cells, idelalisib abrogates the
protective effect of many microenvironmental signals in-
cluding CD40L, BAFF, TNFα, ET1, fibronectin adhesion
as well as contact with stromal cells and NLC [38–40]
(Fig. 1). The PI3Kδ signaling is essential for B cell re-
sponse after BCR stimulation [41, 42]. Accordingly,
when CLL cells were treated with idelalisib, the pro-
survival effect of BCR stimulation was abrogated [39].
Clinical observations in idelalisib-treated CLL patients
evidenced a redistribution of CLL cells from tissue to
peripheral blood, suggesting a possible interference of
idelalisib with leukemic cell migration and adhesion. In
vitro studies demonstrated that idelalisib inhibits CLL
chemotaxis and adhesion to stromal and endothelial
layers [39, 43]. Noteworthy, it was demonstrated that
idelalisib sensitizes CLL to the cytotoxic action of sev-
eral drugs, such as fludarabine, bendamustine anddexamethasone, and also prevents some lenalidomide
effects on CLL, i.e., cell activation, internalization of
CD20 and secretion of pro-angiogenic factors [44, 39].
Moreover, idelalisib dramatically increased apoptosis
mediated by histone deacetylase inhibitors in NHL
and CLL cells [45]. MCL and MM cells show constitu-
tive activation of Akt that is dependent on PI3Kδ sig-
naling. Thus, idelalisib induced apoptosis on MCL and
overcame MM growth conferred by IL6, insulin-like
growth factor 1 and co-culture with marrow stromal
cells [46, 47].
Ibrutinib and idelalisib harnessing
microenvironmental cells
NK cells
NK cells are innate effectors that recognize and eliminate
virally infected and transformed cells, by secreting pre-
formed granules containing perforin and granzymes and
also by inducing apoptosis of target cells throughout acti-
vation of death receptors. Btk is not only critical for the B
development and differentiation but also regulates NK cell
innate function. NK cells up-regulate Btk expression dur-
ing maturation and activation, and NK cells lacking Btk
show reduced toll-like receptor (TLR)-triggered immune
response with low expressions of IFNγ, perforin, and
granzyme B and impaired cytotoxic activity [48]. Btk has
also a critical role in regulating NK activation in response
to antigen-presenting cells [49]. In addition, Itk mediates
calcium mobilization, granule release and cytotoxicity in
Fc receptor (FcR)-stimulated NK [50]. In line with these
data, the inhibition of Btk and Itk by ibrutinib might
impair NK function and counteract the mechanisms of
action of therapeutic anti-CD20 antibodies (rituximab,
obinutuzumab and ofatumumab) including FcR stimula-
tion and antibody-dependent cell-mediated cytotoxicity
(ADCC). Rituximab is currently approved for the treat-
ment of B cell NHL and CLL in combination with
chemotherapy, whereas ofatumumab and obinutuzumab
are in clinical trials. All therapeutic anti-CD20 antibodies
act throughout immune-mediated mechanisms, including
complement-dependent cytotoxicity (CDC), ADCC and
antibody-dependent phagocytosis (ADCP) by macro-
phages and neutrophils, and also through direct cell death
in case of obinutuzumab. Ibrutinib was reported to inhibit
rituximab-induced NK cell cytokine secretion, NK cyto-
toxic effect towards coated tumor cells and also to prevent
FcR-stimulated NK cell degranulation. Thus, it seems that
the concurrent administration of ibrutinib and rituximab
determines an antagonistic effect in vitro, with the reduc-
tion of antitumor efficacy of rituximab as a result of
ibrutinib-mediated inhibition of FcR-stimulated NK cell
function, specifically ADCC [51] (Fig. 2). It is likely that
the ibrutinib-mediated impairment of NK functions is
mainly driven by Itk inhibition. As consequence, selective
Fig. 2 Schematic view of the role of Btk and PI3Kδ molecules in non-malignant cells. The scheme summarizes the main cellular functions, in
which Bruton tyrosine kinase (Btk) phosphoinositol 3 kinase (PI3K) δ molecules are involved in NK cells, T cells, macrophages, and osteoclasts. On
the right section, some data concerning the effects of ibrutinib and idelalisib on these cells are indicated. NK natural killer, TLR toll-like receptor,
CDC complement-dependent cytotoxicity, ADCC antibody-dependent cell-mediated cytotoxicity, IFNγ interferon γ, TCR T cell receptor, OC osteoclasts,
MM multiple myeloma
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overcome the observed antagonistic effect of these agents.
Very recently, De Roit et al. demonstrated that pre-
treatment with ibrutinib does not impair direct cell
death or complement-mediated lysis of leukemia cells
by anti-CD20 antibodies but strongly inhibits all cell-
mediated mechanisms [52].
Idelalisib was reported to inhibit the immune cell-
mediated mechanisms of anti-CD20 antibodies even if at
weaker extent as compared to ibrutinib [52]. In addition,ibrutinib, fostamatinib and idelalisib were reported to
down-regulate CD20 expression in some cell lines and
in primary CLL and MCL samples in another study [53].
Noteworthy, the PI3Kδ-specific signaling has a key role
in NK maturation and cytokine production [54]. In this
contest, idelalisib lacks a direct cytotoxic effect on NK
cells but decreases NK production of IFNγ [38]. However,
in another study, fosfamatinib and ibrutinib, but not
idelalisib, were shown to affect rituximab-induced NK
degranulation and cytotoxicity as well as NK secretion
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and p110γ inhibitor, IPI-145, also affects NK cells by
promoting cell death [55].
In this scenario, it has also to be considered that
in vivo the egress of neoplastic B cells from tissues to
periphery mediated by ibrutinib and other kinase in-
hibitors may expose cells to a more abundant and fully
active complement compartment favoring the CDC in-
duction by concurrent administration of anti-CD20
antibodies, mitigating the potential disadvantage of re-
duced ADCC. Indeed, encouraging clinical results of
ibrutinib in combination with rituximab in high-risk
CLL patients in phase 2 study [6], and idelalisib in
combination with rituximab in a phase 3 study [15],
are reported. However, studies testing different timing
in the administration of the anti-CD20 antibodies relative
to initiation of ibrutinib or idelalisib or modification of
dosing schedules should be carried out to unravel the pos-
sible interactions between these drugs at molecular levels
and thus maximize the clinical efficacy of the therapeutic
combination.
T cells
Tumor immune surveillance hinges upon the capacity to
elicit a robust Th1 and CD8 T cell response that pro-
motes cytotoxic effects with the production of IFNγ and
IL2. CLL subversion of immune response comprises the
disruption of T cell functions with impairment of im-
mune synapse formation, alteration of actin rearrange-
ment and signal transduction, and reciprocal induction
of inhibitory receptors and ligands [56–59]. Moreover,
CLL cells secrete a panel of cytokines that promote the
aberrant recruitment of a Th2-dominant response, thus
interfering with an effective direct T cell cytotoxicity and
also favoring the maintenance of a prosurvival niche for
leukemic cells through IL4, IL10, and CD40 stimulation.
In T cells, three Tec kinases are expressed, Itk, Rlk/
Txk, and Tec. Itk is expressed at highest amounts and
plays the major role in regulating signaling from the
TCR, starting from phosphorylation of PLCγ that leads a
cascade of events comprising the activation of nuclear
factor of activated T cells (NFAT), NF-κB, and MAPK
pathways as well as the induction of calcium mobilization,
reorganization of actin cytoskeleton, synapse formation,
and cell adhesion. Ibrutinib is an irreversible inhibitor of
Itk, leading to a decrease in PLCγ phosphorylation, a down-
stream inactivation of IkBα, JunB, and NFAT signaling, and
a reduction of intracellular calcium flux in response to TCR
stimulation in primary CD4+ cells and in Jurkat T cell line
[60]. In Th1 CD4 and CD8 T cells, Rlk plays a redundant
role to Itk in response to TCR stimulation. As consequence,
ibrutinib at clinical relevant doses is able to influence the
Th1/Th2 polarization of CD4+ population by decreasing
the Th2-dominant transcription factor JunB, whereasinducing the Th1-specific transcription factor T-bet. It
turns out in a prevalence of IFNγ-producing Th1 in respect
to IL4-producing Th2 cells. The Th1 induction was also
sustained by the observation in CLL patients treated with
ibrutinib, showing a decrease level in serum of Th2-
type cytokines such as IL4 and IL10 at day 28 of treatment
compare to baseline. Overall, the study of Dubovsky and
colleagues [60] provides evidence that ibrutinib may
influence T cell function, by skewing T cells from a
Th2-dominant to a Th1 and CD8+ cytotoxic population,
due to a selective Itk inhibition and a compensatory
mechanism mediated by Rlk that remains uninhibited
in Th1 cells (Fig. 2). Accordingly, mice deficient in Itk
showed impairment in Th2 polarization and Th2 cyto-
kine production in response to Th2-inducing agents and
infections in vivo [61, 62].
Cytokine production by T cells is mediated by PI3K
signaling. Idelalisib did not show any direct cytotoxic
effect on T cells, but it could inhibit the production of
several inflammatory cytokines such as IL6, IL10, TNFα,
and CD40L [38]. Similarly, the inhibition of both PI3K
p110δ and p110γ by IPI-145 was reported to reduce the
secretion of IL2, TNFα, and IFNγ by TCR-stimulated T
cells [55]. Few correlative observations are reported in
published clinical trials. Burger et al. showed a reduction
of CD3+CD4+ and CD3+CD8+ T cell count in the per-
iphery of patients treated with ibrutinib and rituximab
after 6 and 12 months of treatment [6]. In phase 1 trials
testing single-agent idelalisib on relapsed/refractory CLL
or refractory indolent NHL, a correlative study did not
show any significant changes in the absolute number of
CD4+/CD3+ T helper cells, CD8+/CD3+ cytotoxic T
cells or CD56+/CD16+/CD3− NK cells in peripheral
blood of treated patients [14, 17].
Macrophages
Macrophages are involved in the essential process of
engulfment and clearing of microbial pathogens. In par-
ticular, the ingestion of IgG-opsonized targets initiates
with the engagement of FcγRs, activation of multiple
downstream signaling pathways and actin polymerization,
thus leading to the formation of phagocytic cup, the exten-
sion and fusion of pseudopods, and the internalization
and maturation of phagosomes, at which the clearing of
pathogens occurs.
Among cytoplasmic tyrosine kinases of Tec family,
macrophages express Btk, Tec and Bmx. The involvement
of Btk in FcγR-mediated phagocytosis was first reported
in monocytes from XLA patients and also in peritoneal
macrophages from Xid mice lacking functional Btk
[63, 64]. Furthermore, Btk seems irrelevant for macro-
phage functions associated with T cell activation such as
antigen presentation, co-stimulation, or production of T
cell-directed cytokines but instead plays a major role in
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of reactive metabolites, production of proinflammatory
cytokines and microbicidal activity.
Btk and Tec kinases are required for optimal FcγR-
mediated phagocytosis. Both kinases are activated
throughout phagocytosis in primary macrophages and
inhibition of Btk by small interfering RNA markedly
reduced Mac-1 activation and FcγR-induced phagocytosis
[65]. In particular, the first stage of Tec kinases activation
rapidly occurs at nascent phagosomes with their recruit-
ment to the membrane through their pleckstrin homology
domain. Btk and Tec are also involved in the transition of
integrin from a cytoskeleton-bound resting to a mobile
state at phagosome cup. It is also likely a subsequent
involvement of Btk and Tec in later stages of phagosome
maturation with distinct roles. Thus, Btk function is
involved in phagocytosis by sustaining the late and
prolonged activation of PLCγ2 [65]. In accordance with
these results, recent studies indicated that pharmaco-
logical inhibition of Btk by ibrutinib is able to impair
the phagocytosis of rituximab-coated CLL cells by mac-
rophages at clinically relevant doses [52, 66] (Fig. 2).
Macrophages also expressed the ubiquitous isoforms of
PI3K, p110α and p110β as well as the hematopoietic
enriched p110δ isoform. PI3K has been demonstrated
to regulate phagocytosis and migration of macrophages
[67]. The inhibition of PI3Kδ by idelalisib was reported
to reduce rituximab-mediated CLL engulfment and also
abrogate macrophage spreading and invasive capacity
mediated by colony stimulating factor-1 [68, 52].
In line with the T cell paradigm of Th1 and Th2 sub-
sets, macrophages polarize in response to different types
of microbial and environmental signals into two subpop-
ulations, i.e., classic inflammatory M1 and alternative
immunosuppressive M2 macrophages [69, 70]. The M1
phenotype is characterized by the expression of pro-
inflammatory cytokine, high production of reactive nitro-
gen, stimulation of Th1 response, and potent activity
against microbes and tumor cells. Conversely, M2 macro-
phages show efficient phagocytic activity, high expression
of scavenging molecules, mannose and galactose re-
ceptors, and involvement in parasite containment, tissue
remodeling and tumor promotion. M1 macrophage
polarization is mediated by STAT1, the p65 subunit of
NF-κB and IRF3, whereas STAT3 and STAT6 mediate
M2 macrophage polarization. Btk is a critical signal
transducer downstream of TLR4 and interferon γ receptor
(IFNGR) by regulating NF-κB and IRF3 activation. As
consequence, Btk is involved in macrophage lineage com-
mitment to inflammatory profile. Accordingly, Btk(−/−)
macrophages show an impaired ability to polarize into
M1 (inflammatory) macrophages through inefficient ac-
tivation of NF-κB p65 following lipopolysaccharide and
IFNγ stimuli, instead showing enhanced induction ofM2-associated markers [71]. As an M2 phenotype charac-
terizes tumor-associated macrophages (TAMs) leading to
low tumoricidal activity, promotion of angiogenesis and
poor prognosis for patients in several tumoral settings [72,
73], it will be of great interest to evaluate the effects of
ibrutinib on macrophage polarization. In particular,
NLCs are round or fibroblast-shaped adherent cells
differentiated from peripheral blood-derived monocytes
in vitro and also detected in lymph nodes (LN) of CLL
patients [74–76]. NLCs share several features with
tumor-associated macrophages and deregulated expres-
sion of genes involved in immunocompetence [77, 75,
78, 79]. Lenalidomide was shown to modify the balance
of NLCs phenotype from a M2-skewed immunosuppressive
towards a M1-skewed inflammatory profile [80]. In this sce-
nario, studies evaluating the effect of ibrutinib on NLCs
and the combination with lenalidomide would be useful.
Osteoclasts
Osteoclasts (OC) originate from bone marrow-derived
monocyte/macrophages precursor cells and are strictly
regulated by the receptor activator of nuclear factor KB
ligand (RANKL), which cooperates with immunorecep-
tor tyrosine-based activation motif (ITAM) signals to
mediate calcium release and then induces the master
transcription factor for osteoclastogenesis, the nuclear
factor of activated T cells c1 (NFATc1). Btk and Tec are
highly expressed in OC and bridge the RANKL and
ITAM signals, thus leading osteoclast differentiation
[81]. In line with the role of Btk in osteoclast function,
studies on Btk mutation disease (XLA in humans and
Xid in mice) clearly revealed that Btk-deficent osteoclasts
do not completely differentiate into mature multinucle-
ated osteoclasts, leading to defective bone resorption
activity [82, 83].
Analogously, the pharmacological blockage of Btk by
ibrutinib impairs the RANKL signaling in OC and
NFATc1 induction, thus reducing the bone resorption.
Noteworthy, ibrutinib treatment significantly inhibits
MM-induced osteolysis of implanted human bone chips
in SCID mice and ameliorates the bone loss in a
RANKL-induced osteoporosis mouse model [32, 84]
(Fig. 2). Myeloma cells have a high capacity to induce
osteolytic bone lesions in patients, especially in the ad-
vance stages, due to the presence of overactive osteo-
clasts and inactive osteoblasts. In this scenario, ibrutinib
may have a potential role in counteract MM-induced
osteoclast iperactivation and bone lysis as well as in
disruption of mutualistic interaction between MM cells
and osteoclasts, by interfering with crucial cytokine and
chemokine signals [32, 85]. Ibrutinib generated abnormal
giant osteoclasts with defective bone erosion activity
and induced OC apoptosis in vitro in long-term culture.
Moreover, Btk inhibition by ibrutinib leads to an aberrant
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tion [32]. It has to be considered that OC obtained from
XLA patients showed an impaired bone resorption activity
in vitro, but conversely, any evidence of alteration in bone
density was detected in patients. This effect seems to
be derived from a compensatory mechanism mediated
by the up-regulation of several inflammatory cytokines
(IL6, IL1β, and TNFα) in XLA patients that re-equilibrates
OC function [83]. Ibrutinib was reported to block the se-
cretion of these multiple inflammatory cytokines in MM
microenvironment, leading to the potential interruption of
the cytokine-mediated compensation of OC activity [32].
Conclusive remarks
Several novel molecules acting as inhibitors of pivotal
tyrosine kinases downstream the BCR signaling cascade
and/or involved in B cell trafficking and homing are rapidly
spreading in the landscape of therapeutic options in B cell
malignancies, in particular in CLL and MCL settings where
current standard therapeutic strategies induce substantial
toxicity and are not curative, with nearly all patients relaps-
ing. In this scenario, the Btk inhibitor ibrutinib and the
PI3Kδ inhibitor idelalisib have demonstrated good safety
profile and promising clinical efficacy in different B cell
malignancies, clearly affecting the survival of neoplastic
B cells by destabilizing the multifactorial platform of
microenvironment signals that commonly sustain the
malignant clone. These agents also delocalize a consistent
fraction of the tumor B cell clone from the protective
tissue compartment to the periphery interfering with
pathogenetic mechanisms of recirculation and homing.
However, it had been immediately clear the limited
capacity of these agents to completely eradicate the
neoplastic clone, even if an improvement in quality of
responses is seen when patients are treated for an ex-
tended period. Noteworthy, the molecular targets of
ibrutinib and idelalisib are not restricted to B cell compart-
ment but regulate key functions in other cellular elements,
i.e., NK, T cells, macrophages and osteoclasts. Neoplastic B
cells deeply modify the architecture of infiltrating tissue
compartment, skewing the functions of surrounding non-
malignant cellular components to generate a protective and
nurturing microenvironment. Moreover, they also modify
the attitude of cells devoted to natural and adoptive
immune response, inducing an immunosuppressive and
immune-tolerant behavior. Deepening the effects of TKIs
on the normal cellular components in the microenviron-
ment of lymphoproliferative disorders might be of extreme
relevance to better understand some unexplained phe-
nomena observed in the clinical setting, first among all,
why TKIs are so efficient, able to quickly reduce lymphoid
mass, but they can obtain a complete response only in a
small minority of cases. Moreover, specific TKI toxicity
could find a good explanation.In conclusion, shedding light into the effects of these
TKIs to non-malignant cellular compartment will help
to define how they modify the nurturing and protective
niches of B cell clone into tissues, giving information for
a more efficient and rational use of TKIs and, import-
antly, suggesting a rational approach for association with
other agents as the classical cytotoxic drugs, monoclonal
antibodies and immune-modulating agents.
Abbreviations
ABC: activated B cell-like subtype; ADCC: antibody-dependent cell-mediated
cytotoxicity; ADCP: antibody-dependent phagocytosis; BCR: B cell receptor;
BR: bendamustine, rituximab; Btk: Bruton tyrosine kinase; CDC: complement-
dependent cytotoxicity; CIT: chemoimmunotherapy; CLL: chronic lymphocytic
leukemia; CR: complete responses; DLBCL: diffuse large B cell lymphoma; FcR: Fc
receptor; FCR: fludarabine, cyclophosphamide and rituximab; FDA: Food and
Drug Administration; FL: follicular lymphoma; HCL: hairy cell leukemia;
IFN: interferon; IFNGR: interferon γ receptor; IL2: interleukin 2;
ITAM: immunoreceptor tyrosine-based activation motif; Itk: inducible T cell
kinase; LN: lymph nodes; LPL: lymphoplasmacytic lymphoma; MAPK: mitogen-
activated protein kinase; MCL: mantle cell lymphoma; MM: multiple myeloma;
MOA: mode of action; MZL: marginal zone lymphoma; NFAT: nuclear factor of
activated T cells; NFATc1: nuclear factor of activated T cells c1; NF-κB: nuclear
factor κB; NHL: non-Hodgkin lymphoma; NK: natural killer; NLCs: nurse-like cells;
OC: osteoclasts; ORR: overall response rate; PFS: progression-free survival;
PI3K: phosphoinositol 3 kinase; PLCγ: phospholipase Cγ; PR: partial response;
RANKL: receptor activator of nuclear factor KB ligand; R-CHOP: rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone; Rlk: resting
lymphocyte kinase; SLL: small lymphocytic lymphoma; Tec: tyrosine kinase
expressed in hepatocellular carcinoma; TKIs: tyrosine kinase inhibitors; TLR: toll-like
receptor; TNF: tumor necrosis factor; WM: Waldenström macroglobulemia;
Xid: X-linked immunodeficiency; XLA: X-linked agammaglobulinemia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RMaf conceived and wrote the manuscript. SF, SM, LP, ML and RMar drafted
the manuscript and approved the final version.
Acknowledgements
This work was supported by Associazione Italiana per la Ricerca sul Cancro
(AIRC IG10621-RMar, SF) Milan, and Ricerca Finalizzata Giovani Ricercatori
2011–2012, Ministero della Salute (GR-2011-02349282, RMaf), Rome, Italy.
Received: 9 April 2015 Accepted: 14 May 2015
References
1. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat
Rev Immunol. 2002;2(12):945–56. doi:10.1038/nri955.
2. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton
tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in
patients with relapsed/refractory B-cell malignancies. J Clin Oncol.
2013;31(1):88–94. doi:10.1200/JCO.2012.42.7906.
3. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting
BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med.
2013;369(1):32–42. doi:10.1056/NEJMoa1215637.
4. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid
leukemia. N Engl J Med. 2014;371(3):213–23. doi:10.1056/NEJMoa1400376.
5. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al.
Three-year follow-up of treatment-naive and previously treated patients
with CLL and SLL receiving single-agent ibrutinib. Blood. 2015.
doi:10.1182/blood-2014-10-606038.
6. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY,
et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk
chronic lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet
Oncology. 2014;15(10):1090–9. doi:10.1016/S1470-2045(14)70335-3.
Maffei et al. Journal of Hematology & Oncology  (2015) 8:60 Page 11 of 137. O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA,
et al. Ibrutinib as initial therapy for elderly patients with chronic
lymphocytic leukaemia or small lymphocytic lymphoma: an open-label,
multicentre, phase 1b/2 trial. The Lancet Oncology. 2014;15(1):48–58.
doi:10.1016/S1470-2045(13)70513-8.
8. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A et al. The
Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, with
chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Blood. 2015. doi:10.1182/blood-2014-09-585869.
9. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib
for previously untreated and relapsed or refractory chronic lymphocytic
leukaemia with TP53 aberrations: a phase 2, single-arm trial. The Lancet
Oncology. 2015;16(2):169–76. doi:10.1016/S1470-2045(14)71182-9.
10. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, et al. A
phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with
untreated and relapsed/refractory non-Hodgkin lymphoma. Blood.
2015;125(2):242–8. doi:10.1182/blood-2014-08-597914.
11. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with
ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med.
2013;369(6):507–16. doi:10.1056/NEJMoa1306220.
12. Wilson WH, Gerecitano JF, Goy A, De Vos S, Kenkre VP, Barr PM, et al. The
Bruton’s Tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), Has
preferential activity in the ABC subtype of relapsed/refractory De novo
diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter,
open-label, phase 2 study. Blood. 2012;120:686.
13. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S,
et al. Combination of ibrutinib with rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive
patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-
randomised, phase 1b study. The Lancet Oncology. 2014;15(9):1019–26.
doi:10.1016/S1470-2045(14)70311-0.
14. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND,
et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for
relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):
3390–7. doi:10.1182/blood-2013-11-535047.
15. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J
Med. 2014;370(11):997–1007. doi:10.1056/NEJMoa1315226.
16. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A
phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/
refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–405.
doi:10.1182/blood-2013-11-537555.
17. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, et al. Idelalisib,
a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for
previously treated indolent non-Hodgkin lymphoma. Blood.
2014;123(22):3406–13. doi:10.1182/blood-2013-11-538546.
18. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ,
et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent
lymphoma. N Engl J Med. 2014;370(11):1008–18. doi:10.1056/NEJMoa1314583.
19. Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in btk
in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet.
1998;62(5):1034–43. doi:10.1086/301828.
20. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L,
et al. Mutation of unique region of Bruton’s tyrosine kinase in
immunodeficient XID mice. Science. 1993;261(5119):358–61.
21. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA,
et al. Bruton’s tyrosine kinase (BTK) function is important to the
development and expansion of chronic lymphocytic leukemia (CLL). Blood.
2014;123(8):1207–13. doi:10.1182/blood-2013-07-515361.
22. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic
leukemia cell survival and tissue homing in vitro and in vivo. Blood.
2012;119(5):1182–9. doi:10.1182/blood-2011-10-386417.
23. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S,
et al. Bruton tyrosine kinase represents a promising therapeutic target for
treatment of chronic lymphocytic leukemia and is effectively targeted by
PCI-32765. Blood. 2011;117(23):6287–96. doi:10.1182/blood-2011-01-328484.
24. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The
clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and
chemokine-controlled adhesion and migration in chronic lymphocytic
leukemia. Blood. 2012;119(11):2590–4. doi:10.1182/blood-2011-11-390989.25. Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, et al.
Modeling tumor-host interactions of chronic lymphocytic leukemia in
xenografted mice to study tumor biology and evaluate targeted
therapy. Leukemia. 2013;27(12):2311–21. doi:10.1038/leu.2013.131.
26. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al.
Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation
in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286–95.
doi:10.1182/blood-2014-02-548610.
27. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition
targets in vivo CLL proliferation through its effects on B-cell receptor signaling
activity. Leukemia. 2014;28(3):649–57. doi:10.1038/leu.2013.358.
28. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, et al.
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor
ibrutinib. Blood. 2014;123(26):4132–5. doi:10.1182/blood-2014-02-554220.
29. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic
active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature.
2010;463(7277):88–92. doi:10.1038/nature08638.
30. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and
is efficacious in models of autoimmune disease and B-cell malignancy. Proc
Natl Acad Sci U S A. 2010;107(29):13075–80. doi:10.1073/pnas.1004594107.
31. Yang Y, Shaffer 3rd AL, Emre NC, Ceribelli M, Zhang M, Wright G, et al.
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell
lymphoma. Cancer Cell. 2012;21(6):723–37. doi:10.1016/j.ccr.2012.05.024.
32. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, et al. Bruton tyrosine
kinase inhibition is a novel therapeutic strategy targeting tumor in the bone
marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877–87.
doi:10.1182/blood-2011-12-396853.
33. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances
bortezomib and lenalidomide activities through NF-kappaB. Cell Signal.
2013;25(1):106–12. doi:10.1016/j.cellsig.2012.09.008.
34. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The Bruton tyrosine
kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival,
proliferation and B cell receptor signalling: a new therapeutic approach. Br J
Haematol. 2014;166(2):177–88. doi:10.1111/bjh.12867.
35. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development,
differentiation and activation. Nat Rev Immunol. 2003;3(4):317–30.
doi:10.1038/nri1056.
36. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K
isoforms: insights from gene-targeted mice. Trends Biochem Sci.
2005;30(4):194–204. doi:10.1016/j.tibs.2005.02.008.
37. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al.
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in
the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
Blood. 2002;100(10):3741–8. doi:10.1182/blood-2002-02-0539.
38. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al.
Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising
preclinical activity in chronic lymphocytic leukemia by antagonizing
intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):
2078–88. doi:10.1182/blood-2010-02-271171.
39. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating
MJ, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits
B-cell receptor signaling and chemokine networks in chronic lymphocytic
leukemia. Blood. 2011;118(13):3603–12. doi:10.1182/blood-2011-05-352492.
40. Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, et al.
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic
leukemia B cells through ETA receptor. PLoS One. 2014;9(6):e98818.
doi:10.1371/journal.pone.0098818.
41. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3
kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573–86.
doi:10.1016/j.cell.2009.08.041.
42. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Wang D, et al. Essential,
nonredundant role for the phosphoinositide 3-kinase p110delta in signaling
by the B-cell receptor complex. Mol Cell Biol. 2002;22(24):8580–91.
43. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O’Brien S, et al. The
PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion
of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal
cells. PLoS One. 2013;8(12):e83830. doi:10.1371/journal.pone.0083830.
44. Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al.
The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory
Maffei et al. Journal of Hematology & Oncology  (2015) 8:60 Page 12 of 13effects of lenalidomide in chronic lymphocytic leukemia. Blood.
2011;117(16):4323–7. doi:10.1182/blood-2010-11-315705.
45. Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, et al. The
phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically
potentiates histone deacetylase inhibitor-induced proliferation inhibition
and apoptosis through the inactivation of PI3K and extracellular signal-
regulated kinase pathways. Br J Haematol. 2013;163(1):72–80.
doi:10.1111/bjh.12498.
46. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ,
et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor
for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular
viability. Blood. 2011;117(2):591–4. doi:10.1182/blood-2010-03-275305.
47. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/
p110{delta} is a novel therapeutic target in multiple myeloma. Blood.
2010;116(9):1460–8. doi:10.1182/blood-2009-06-222943.
48. Bao Y, Zheng J, Han C, Jin J, Han H, Liu Y, et al. Tyrosine kinase Btk is
required for NK cell activation. J Biol Chem. 2012;287(28):23769–78.
doi:10.1074/jbc.M112.372425.
49. Ni Gabhann J, Spence S, Wynne C, Smith S, Byrne JC, Coffey B, et al. Defects
in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic
cell-induced IFN-gamma production by natural killer cells. Clin Immunol.
2012;142(3):373–82. doi:10.1016/j.clim.2011.12.009.
50. Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. Differential
regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase
Itk. J Immunol. 2007;178(6):3575–82.
51. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al. Ibrutinib
antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood.
2014;123(12):1957–60. doi:10.1182/blood-2014-01-547869.
52. Roit FD, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, et al. Ibrutinib
interferes with the cell-mediated anti-tumor activities of therapeutic CD20
antibodies: implications for combination therapy. Haematologica.
2015;100(1):77–86. doi:10.3324/haematol.2014.107011.
53. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, et al.
B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor
activity of anti-CD20 monoclonal antibodies. Leukemia. 2014;28(5):1163–7.
doi:10.1038/leu.2014.12.
54. Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S. The p110 delta of PI3K
plays a critical role in NK cell terminal maturation and cytokine/chemokine
generation. J Exp Med. 2008;205(10):2419–35. doi:10.1084/jem.20072327.
55. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, et al. IPI-145
antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic
leukemia cells. Blood. 2014;124(24):3583–6. doi:10.1182/blood-2014-07-587279.
56. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al.
Chronic lymphocytic leukemia T cells show impaired immunological
synapse formation that can be reversed with an immunomodulating drug.
J Clin Invest. 2008;118(7):2427–37. doi:10.1172/JCI35017.
57. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce
impaired T-cell immunologic synapse function in chronic lymphocytic
leukemia that can be blocked with lenalidomide: establishing a reversible
immune evasion mechanism in human cancer. Blood. 2012;120(7):1412–21.
doi:10.1182/blood-2012-02-411678.
58. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic
lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility
by altering Rho GTPase signaling that is reversible with lenalidomide. Blood.
2013;121(14):2704–14. doi:10.1182/blood-2012-08-448332.
59. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, et al.
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of
chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad
Sci U S A. 2009;106(15):6250–5. doi:10.1073/pnas.0901166106.
60. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y,
et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a
Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.
doi:10.1182/blood-2013-06-507947.
61. Schaeffer EM, Yap GS, Lewis CM, Czar MJ, McVicar DW, Cheever AW, et al.
Mutation of Tec family kinases alters T helper cell differentiation. Nat
Immunol. 2001;2(12):1183–8. doi:10.1038/ni734.
62. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al.
Impaired NFATc translocation and failure of Th2 development in Itk-deficient
CD4+ T cells. Immunity. 1999;11(4):399–409.
63. Amoras AL, Kanegane H, Miyawaki T, Vilela MM. Defective Fc-, CR1- and
CR3-mediated monocyte phagocytosis and chemotaxis in common variableimmunodeficiency and X-linked agammaglobulinemia patients. J Investig
Allergol Clin Immunol. 2003;13(3):181–8.
64. Mukhopadhyay S, Mohanty M, Mangla A, George A, Bal V, Rath S, et al.
Macrophage effector functions controlled by Bruton’s tyrosine kinase are
more crucial than the cytokine balance of T cell responses for microfilarial
clearance. J Immunol. 2002;168(6):2914–21.
65. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI.
Dual functions of Bruton’s tyrosine kinase and Tec kinase during
Fcgamma receptor-induced signaling and phagocytosis. J Immunol.
2008;181(1):288–98.
66. Borge M, Almejun MB, Podaza E, Colado A, Fernandez Grecco H, Cabrejo M
et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells
from chronic lymphocytic leukemia patients by human macrophages.
Haematologica. 2015. doi:10.3324/haematol.2014.119669.
67. Papakonstanti EA, Zwaenepoel O, Bilancio A, Burns E, Nock GE,
Houseman B, et al. Distinct roles of class IA PI3K isoforms in primary
and immortalised macrophages. J Cell Sci. 2008;121(Pt 24):4124–33.
doi:10.1242/jcs.032763.
68. Mouchemore KA, Sampaio NG, Murrey MW, Stanley ER, Lannutti BJ, Pixley FJ.
Specific inhibition of PI3K p110delta inhibits CSF-1-induced macrophage
spreading and invasive capacity. FEBS J. 2013;280(21):5228–36.
doi:10.1111/febs.12316.
69. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization:
tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol. 2002;23(11):549–55.
70. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas.
J Clin Invest. 2012;122(3):787–95. doi:10.1172/JCI59643.
71. Ni Gabhann J, Hams E, Smith S, Wynne C, Byrne JC, Brennan K, et al. Btk
regulates macrophage polarization in response to lipopolysaccharide. PLoS
One. 2014;9(1):e85834. doi:10.1371/journal.pone.0085834.
72. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated
macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med.
2010;362(10):875–85. doi:10.1056/NEJMoa0905680.
73. Chen J, Yao Y, Gong C, Yu F, Su S, Liu B, et al. CCL18 from tumor-associated
macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell.
2011;19(4):541–55. doi:10.1016/j.ccr.2011.02.006.
74. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike”
cells that differentiate in the context of chronic lymphocytic leukemia.
Blood. 2002;99(3):1030–7.
75. Ysebaert L, Fournie JJ. Genomic and phenotypic characterization of nurse-like
cells that promote drug resistance in chronic lymphocytic leukemia. Leuk
Lymphoma. 2011;52(7):1404–6. doi:10.3109/10428194.2011.568078.
76. Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A, et al. Extracellular
HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic
leukemia. Blood. 2014;123(11):1709–19. doi:10.1182/blood-2013-10-529610.
77. Filip AA, Cisel B, Koczkodaj D, Wasik-Szczepanek E, Piersiak T, Dmoszynska A.
Circulating microenvironment of CLL: are nurse-like cells related to
tumor-associated macrophages? Blood Cells Mol Dis. 2013;50(4):263–70.
doi:10.1016/j.bcmd.2012.12.003.
78. Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, et al. Chronic
lymphocytic leukemia nurse-like cells express hepatocyte growth factor
receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of
immunosuppressive type 2 skewed macrophages. Haematologica.
2014;99(6):1078–87. doi:10.3324/haematol.2013.091405.
79. Bhattacharya N, Diener S, Idler IS, Rauen J, Habe S, Busch H, et al. Nurse-like
cells show deregulated expression of genes involved in immunocompetence.
Br J Haematol. 2011;154(3):349–56. doi:10.1111/j.1365-2141.2011.08747.x.
80. Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E et al.
Lenalidomide interferes with tumor-promoting properties of nurse-like
cells in chronic lymphocytic leukemia. Haematologica. 2014.
doi:10.3324/haematol.2014.113217.
81. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al.
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking
RANK and ITAM signals. Cell. 2008;132(5):794–806. doi:10.1016/
j.cell.2007.12.037.
82. Lee SH, Kim T, Jeong D, Kim N, Choi Y. The tec family tyrosine kinase Btk
Regulates RANKL-induced osteoclast maturation. J Biol Chem.
2008;283(17):11526–34. doi:10.1074/jbc.M708935200.
83. Danks L, Workman S, Webster D, Horwood NJ. Elevated cytokine production
restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner
Res. 2011;26(1):182–92. doi:10.1002/jbmr.210.
Maffei et al. Journal of Hematology & Oncology  (2015) 8:60 Page 13 of 1384. Shinohara M, Chang BY, Buggy JJ, Nagai Y, Kodama T, Asahara H, et al.
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against
osteoclast-mediated bone loss. Bone. 2014;60:8–15. doi:10.1016/j.bone.2013.11.025.
85. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, et al. Role of
Bruton’s tyrosine kinase in myeloma cell migration and induction of bone
disease. Am J Hematol. 2013;88(6):463–71. doi:10.1002/ajh.23433.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
